Skip to content
Life Sciences Series C Founded 2008

GenomeDx Biosciences

GenomeDx develops and commercializes genomic tests for urologic cancers. Its proprietary Decipher GRID platform is a clinically annotated genomic expression database, and its flagship product predicts the probability of prostate cancer metastasis after surgery by measuring expression levels of 22 biomarkers. Founded in 2008 in San Diego, United States, the company has raised $69.7M in Series C funding from investors…

📍 San Diego, United States · Genomics,

Funding snapshot

Last roundSeries C
Amount$8M
Date15 May 2020
Total raised$70M
Team size159

About

GenomeDx develops and commercializes genomic tests for urologic cancers. Its proprietary Decipher GRID platform is a clinically annotated genomic expression database, and its flagship product predicts the probability of prostate cancer metastasis after surgery by measuring expression levels of 22 biomarkers. Founded in 2008 in San Diego, United States, the company has raised $69.7M in Series C funding from investors including Merck Global Health Innovation Fund and Baird Capital. Founded in 2008, headquartered in San Diego, United States. The team comprises 159 (Dec 31, 2. The company operates in Life Sciences > Genomics, Life Sciences > Oncology, Life Sciences > Clinical Genomics, Life Scien.

Business model

Oncology > In-Vitro Diagnostic Tests > Prostate Cancer,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Hybridization-based > Microarrays,

Life Sciences Platforms and Tools > Research Assays > Drug Discovery > Microarrays

Institutional investors

Calibrium CD-Venture Baird Capital Merck Global Health Innovation Fund CRG WUTIF Capital Tekla Capital Management EMBL Ventures

Latest coverage

No articles yet.

Raising like GenomeDx Biosciences?

Analyze your pitch deck before your next raise.

Analyze My Deck →